{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T14:42:52Z","timestamp":1773153772555,"version":"3.50.1"},"reference-count":16,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2011,11,10]],"date-time":"2011-11-10T00:00:00Z","timestamp":1320883200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2012,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This Phase 1\/2 study aimed to determine optimal doses of daunorubicin (DNR; mg\/m<jats:sup>2<\/jats:sup>) and cytarabine (mg\/m<jats:sup>2<\/jats:sup>) to be combined with fractionated doses of gemtuzumab ozogamicin (GO, Mylotarg\u00ae; 3 mg\/m<jats:sup>2<\/jats:sup> on day 1, 4, and 7) satisfying safety requirements. Three dose levels of DNR\/AraC were investigated namely (45, 100), (60, 100), and (60, 200). Patients included were acute myeloid leukemia in first relapse, aged 50\u201370 years. Hematological recovery was 31 days for neutrophil and 32 days for platelet counts. A documented infectious episode &gt; Grade 2 occurred in 11\/20 patients (55%). None of the 20 patients had signs of veno\u2010occlusive disease. Overall, eleven patients reached complete remission (CR), two CR with incomplete platelets recovery. The results showed that combination of fractionated GO doses with DNR at 60 mg\/m<jats:sup>2<\/jats:sup>\/d for 3 days and cytarabine at 200 mg\/m<jats:sup>2<\/jats:sup>\/d for 7 days is tolerable and could be further investigated in the front\u2010line therapy. Am. J. Hematol., 2012. \u00a9 2011 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/ajh.22201","type":"journal-article","created":{"date-parts":[[2011,9,28]],"date-time":"2011-09-28T01:19:53Z","timestamp":1317172793000},"page":"62-65","source":"Crossref","is-referenced-by-count":30,"title":["Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50\u201370\u2010year old: A phase 1\/2 study of the acute leukemia French association"],"prefix":"10.1002","volume":"87","author":[{"given":"Hassan","family":"Farhat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oumedaly","family":"Reman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Raffoux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celine","family":"Berthon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9cile","family":"Pautas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leila","family":"Kammoun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvain","family":"Chantepie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claude","family":"Gardin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Rousselot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvie","family":"Chevret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herv\u00e9","family":"Dombret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvie","family":"Castaigne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,11,10]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0178"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-235358"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401663"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21326"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404434"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.10.3197"},{"key":"e_1_2_5_8_2","first-page":"1","volume-title":"Guidelines for cancer cytogenetics. Mitelman F, Supplement to an International System for Human Cytogenetic Nomenclature","author":"ISCN (International System for Human Cytogenetic Nomenclature)","year":"1991"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24442"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.036"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.7.2322"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.2652"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-095844"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.4310"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-05-1620"},{"key":"e_1_2_5_16_2","first-page":"341a","article-title":"Gemtuzumab ozogamicin (Mylotarg) in combination induction chemotherapy for the treatment of patients with de novo acute myeloid leukemia: Two age\u2010specific phase 2 trials","volume":"102","author":"De Angelo DJ","year":"2003","journal-title":"Blood"},{"key":"e_1_2_5_17_2","first-page":"114","article-title":"Preliminary results of Southwest oncology group study S0106: An International Intergroup Phase 3 Randomized Trial Comparing the Addition of Gemtuzumab Ozogamicin to Standard Induction Therapy Versus Standard Induction Therapy Followed by a Second Randomization to Post\u2010Consolidation Gemtuzumab Ozogamicin Versus No Additional Therapy for Previously Untreated Acute Myeloid Leukemia","author":"Petersdorf S","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.22201","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.22201","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T20:55:52Z","timestamp":1698785752000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.22201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,10]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["10.1002\/ajh.22201"],"URL":"https:\/\/doi.org\/10.1002\/ajh.22201","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,10]]}}}